OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Garfall Discusses CAR T-Cell Therapy in Multiple Myeloma

November 22nd 2019

Alfred L. Garfall, MD, MS, discusses the potential of CAR T-cell therapy in multiple myeloma.

Dr. Furman on Frontline Treatment Selection in CLL

November 22nd 2019

Richard R. Furman, MD, discusses the use of BTK inhibitors in chronic lymphocytic leukemia.

Dr. Somer on the Expansion of Biosimilars in Oncology

November 22nd 2019

Bradley G. Somer, MD, discusses the importance of taking a proactive approach towards the use of biosimilars in oncology.

Dr. Feldman on Prophylactic Cranial Irradiation in SCLC

November 21st 2019

Lawrence E. Feldman, MD, discusses utilizing prophylactic cranial irradiation in limited-stage and extensive-stage small cell lung cancer.

Dr. Copeland on the Etiology of Ovarian Cancer

November 21st 2019

Larry J. Copeland, MD, discusses the etiology of ovarian cancer.

Dr. Chari on Transplant Eligibility in Multiple Myeloma

November 21st 2019

Ajai Chari, MD, discusses transplant eligibility in multiple myeloma.

Dr. Mato on Ibrutinib-Based Combinations in CLL

November 21st 2019

Anthony R. Mato, MD, MSCE, discusses ibrutinib-based combinations in chronic lymphocytic leukemia.

Dr. Salani Discusses Potential Treatment Modalities in Cervical Cancer

November 21st 2019

Ritu Salani, MD, discusses the potential of targeted therapy and immunotherapy in cervical cancer.

Dr. Vokes Discusses Unanswered Questions from the PACIFIC Trial in NSCLC

November 21st 2019

Everett E. Vokes, MD, discusses unanswered questions from the phase III PACIFIC trial in stage III non–small cell lung cancer.

Dr. Kaubisch on the REACH Trials in HCC

November 21st 2019

Andreas Kaubisch, MD, discusses the phase III REACH and REACH-2 trials in advanced hepatocellular carcinoma.

Dr. Cohen on Fixed-Duration Therapy in CLL

November 21st 2019

Jonathon B. Cohen, MD, MS, discusses fixed-duration therapy in chronic lymphocytic leukemia.

Dr. Koo on New Management Strategies for Prostate Cancer

November 21st 2019

Phillip J. Koo, MD, discusses new management strategies for patients with prostate cancer.

Dr. Somer on Education for Biosimilars

November 21st 2019

Bradley G. Somer, MD, discusses the education surrounding biosimilars in oncology.

Dr. Ocean Discusses the Use of ctDNA in Pancreatic Cancer

November 20th 2019

Allyson Ocean, MD, discusses the use of circulating tumor DNA in pancreatic cancer.

Dr. Bryce on Potential Biomarkers of Response to Immunotherapy in Prostate Cancer

November 20th 2019

Alan H. Bryce, MD, discusses potential biomarkers of response to immunotherapy in prostate cancer.

Dr. Castle on Minimally Invasive Surgical Approaches in RCC

November 20th 2019

Erik P. Castle, MD, discusses minimally invasive surgical approaches in renal cell carcinoma.

Dr. Piotrowska on Treatment for EGFR-Mutant NSCLC

November 20th 2019

Zofia Piotrowska, MD, MHS, discusses treatment strategies for EGFR-mutant non–small cell lung cancer.

Dr. Garfall on Quadruplet Regimen in Multiple Myeloma

November 20th 2019

Alfred L. Garfall, MD, provides insight on the FDA approval of daratumumab added to bortezomib, thalidomide, and dexamethasone for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Dr. Robson on Differences Between Biosimilars and Biologics in Oncology

November 20th 2019

Mark E. Robson, MD, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.

Dr. Braunstein on Reclassifying Ultra High-Risk Smoldering Multiple Myeloma

November 20th 2019

Marc J. Braunstein, MD, PhD, discusses the ultra–high-risk patient population in smoldering multiple myeloma.